Fig. 2

Latent class models according to treatment received. The trajectories in a 5-class model are shown for the whole cohort, those patients receiving epratuzumab (at either dose) or patients receiving placebo respectively. In the epratuzumab group, there are trajectories similar to the whole cohort. In the placebo group, the yellow group flares earlier than in the whole cohort. The HDA group is not observed in the placebo model, but instead a second flare group with a later flare is seen (blue). The 3 trajectories of NR, SR and RR are similar between cohorts, although the RR and SR show greater separation in the placebo group.